Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
982.29
+14.31 (+1.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
36
37
Next >
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
March 23, 2023
Via
Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
March 23, 2023
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Via
The Motley Fool
Why Are Stocks Up Today?
March 23, 2023
Stocks are up today as investors react to the latest news from the Federal Reverse concerning a new interest rate increase.
Via
InvestorPlace
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
March 23, 2023
Via
Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
March 23, 2023
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.
Via
InvestorPlace
This Is What Whales Are Betting On Regeneron Pharmaceuticals
March 23, 2023
Via
Benzinga
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
March 23, 2023
Bloomberg
Via
Benzinga
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
March 23, 2023
The companies' Dupixent reduced exacerbations by 30%.
Via
Investor's Business Daily
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
March 23, 2023
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial.
Via
Benzinga
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
March 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Value Stocks Worth Buying at These 52-Week Highs
March 22, 2023
While these value stocks to buy are trading near their 52-week highs, they still have plenty of gas left in the tank for investors.
Via
InvestorPlace
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
March 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
March 16, 2023
Via
Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
March 14, 2023
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
March 09, 2023
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
March 07, 2023
Via
Benzinga
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
March 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
March 18, 2023
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had...
Via
Talk Markets
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
March 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
March 16, 2023
It's still unclear whether CMS will include those drugs in its negotiation list.
Via
Investor's Business Daily
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
March 06, 2023
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
March 14, 2023
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
March 09, 2023
Regeneron and Sarepta Therapeutics have been on fire so far this year.
Via
The Motley Fool
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
March 07, 2023
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
March 06, 2023
The French drug company got the nod for a hemophilia treatment.
Via
The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
March 01, 2023
Via
Benzinga
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
February 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
February 24, 2023
Startling cancer vaccine results from Moderna may point to the next big thing in biotech.
Via
Investor's Business Daily
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
36
37
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.